Insider Selling Sparks Questions at uniQure Recent insider sales at uniQure, including transactions by top executives, have raised eyebrows. Despite a 118% stock surge over six months, these sales, aimed at covering tax obligations, suggest cautious sentiment. Analysts remain optimistic, citing the company’s strong gene therapy pipeline and upcoming regulatory milestones.23